文献速递脑血管病神经重症与神经感染

血糖控制与急性缺血性卒中溶栓后症状性颅内出血风险:SHINE试验分析

Glucose Control and Risk of Symptomatic Intracerebral Hemorrhage Following Thrombolysis for Acute Ischemic Stroke: A SHINE Trial Analysis.
PubMed 文献 · Neurology · 2024-04-16

该研究为SHINE试验的预设分析,纳入1151例高血糖急性缺血性卒中患者,其中725例接受溶栓治疗。溶栓后症状性颅内出血发生率为3.6%,强化胰岛素治疗与标准滑动刻度治疗相比无显著差异(OR 1.10,95%CI 0.60-2.01,p=0.697)。但溶栓后早期血糖每升高10 mg/dL,症状性颅内出血风险增加(OR 1.08,95%CI 1.03-1.14,p=0.004)。

要点

  • 强化胰岛素治疗未降低溶栓后症状性颅内出血风险
  • 溶栓后早期血糖升高与症状性颅内出血风险增加相关
  • 高龄且卒中严重者中该关联更强

核心结论

  • 强化胰岛素治疗与标准滑动刻度治疗相比,未降低溶栓后症状性颅内出血风险。
  • 溶栓后早期高血糖与症状性颅内出血风险升高相关,尤其在高龄和卒中严重患者中。

研究设计与样本

  • SHINE试验的预设分析,纳入发病12小时内的高血糖急性缺血性卒中患者1151例,其中725例接受溶栓治疗。
  • 患者随机接受强化胰岛素治疗(目标范围80-130 mg/dL)或标准滑动刻度治疗(80-179 mg/dL),持续72小时,按是否溶栓分层。
  • 由三名认证血管神经科医生独立评审7天内发生的症状性颅内出血事件,定义为NIHSS评分恶化≥4分。

主要发现

  • 溶栓后症状性颅内出血发生率为3.6%,强化治疗组为3.0%,标准治疗组为4.3%,OR 1.10(95%CI 0.60-2.01),p=0.697。
  • 溶栓后最初12小时内,血糖每升高10 mg/dL,症状性颅内出血的比值增加(OR 1.08,95%CI 1.03-1.14,p=0.004)。
  • 正常范围(80-130 mg/dL)血糖测量比例越高,症状性颅内出血的比值越低(OR 0.89,95%CI 0.80-0.99,p=0.030)。
  • 上述关联在高风险组(年龄大于60岁且NIHSS≥8)中最强。

局限性

  • 需要进一步的前瞻性研究来评估接受血管内治疗的高血糖卒中患者的症状性颅内出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Baseline hyperglycemia is associated with worse outcomes in acute ischemic stroke (AIS), including higher risk of symptomatic intracerebral hemorrhage (sICH) following treatment with thrombolysis. Prospective data are lacking to inform management of post-thrombolysis hyperglycemia. In a prespecified analysis from the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial of hyperglycemic stroke management, we hypothesized that post-thrombolysis hyperglycemia is associated with a higher risk of sICH. METHODS: Hyperglycemic AIS patients <12 hours onset were randomized to intensive insulin (target range 80-130 mg/dL) vs standard sliding scale (80-179 mg/dL) over a 72-hour period, stratified by treatment with thrombolysis. Three board-certified vascular neurologists independently reviewed all sICH events occurring within 7 days, defined by neurologic deterioration of ≥4 points on the NIH Stroke Scale (NIHSS). Associations between blood glucose control and sICH were analyzed using logistic regression accounting for NIHSS, age, systolic blood pressure, onset to thrombolysis time, and endovascular therapy (odds ratios [OR], 95% CI). Additional analysis compared patients in a high-risk group (age older than 60 years and NIHSS ≥8) vs all others. Categorical variables and outcomes were compared using the χ2 test (p < 0.05). RESULTS: Of 1151 SHINE participants, 725 (63%) received thrombolysis (median age 65 years, 46% women, 29% Black, 18% Hispanic). The median NIHSS was 7, baseline blood glucose was 187 (interquartile range 153-247) mg/dL, and 80% were diabetic. Onset to thrombolysis time was 2.2 hours (1.6-2.9). Post-thrombolysis sICH occurred in 3.6% (3.0% intensive vs 4.3% standard glucose control, OR 1.10, 0.60-2.01, p = 0.697). In the first 12 hours, every 10 mg/dL higher glucose increased the odds of sICH (OR 1.08, 1.03-1.14, p = 0.004), and a greater proportion of glucose measures in the normal range (80-130 mg/dL) decreased the odds of sICH (0.89, 0.80-0.99, p = 0.030). These associations were strongest in the high-risk group (age older than 60 years and NIHSS ≥8). DISCUSSION: In this prespecified analysis from the SHINE trial, intensive insulin therapy was not associated with a reduced risk of post-thrombolysis sICH compared with standard sliding scale. However, early post-thrombolysis hyperglycemia was associated with a higher risk of sICH overall, particularly in older patients with more severe strokes. Further prospective research is warranted to address the risk of sICH in hyperglycemic stroke patients undergoing endovascular therapy. TRIAL REGISTRATION INFORMATION: NCT01369069.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Southerland AM, Mayer SA, Chiota-McCollum NA, et al. Glucose Control and Risk of Symptomatic Intracerebral Hemorrhage Following Thrombolysis for Acute Ischemic Stroke: A SHINE Trial Analysis. Neurology. 2024. PMID: 38626363. doi:10.1212/WNL.0000000000209323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。